At Fierce Biotech, we love a big M&A deal, but valuation does not always equal the most exciting.  

In this week's episode of "The Top Line," Fierce Biotech’s Annalee Armstrong and James Waldron discuss what they think are the best and smartest acquisitions in recent years.  

From obesity to radiopharmaceuticals, they give you the Fierce Biotech team’s thoughts on who got the best deal. 

To learn more about the topics in this episode:  
Top 10 smartest deals in biopharma

At Fierce Biotech, we love a big M&amp;A deal, but valuation does not always equal the most exciting.  
In this week's episode of "The Top Line," Fierce Biotech’s Annalee Armstrong and James Waldron discuss what they think are the best and smartest acquisitions in recent years.  
From obesity to radiopharmaceuticals, they give you the Fierce Biotech team’s thoughts on who got the best deal. 
To learn more about the topics in this episode:  
<ul>
<li><a href="https://www.fiercebiotech.com/biotech/smartest-pharma-acquisitions" data-cke-saved-href="https://www.fiercebiotech.com/biotech/smartest-pharma-acquisitions">Top 10 smartest deals in biopharma</a> </li>
</ul>

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

The best biopharma M&A deals

In this week’s episode of “The Top Line,” Fierce Pharma’s Zoey Becker sits down with Bobby Sheng, the CEO of Bora Pharmaceuticals, to discuss the concept of “friend-shoring” in drug manufacturing.

"Friend-shoring" involves conducting manufacturing processes in countries considered friendly or allied. Sheng discusses the criteria for deeming a country “friendly” and explores whether this strategy could help address drug supply shortages.

To learn more about the topics in this episode:
Bora plants its flag in the US with $210M acquisition of generics manufacturer Upsher-Smith
Emergent, pivoting away from CDMO business, sells Baltimore plant to acquisitive Bora for $30M

In this week’s episode of “The Top Line,” Fierce Pharma’s Zoey Becker sits down with Bobby Sheng, the CEO of Bora Pharmaceuticals, to discuss the concept of “friend-shoring” in drug manufacturing.
"Friend-shoring" involves conducting manufacturing processes in countries considered friendly or allied. Sheng discusses the criteria for deeming a country “friendly” and explores whether this strategy could help address drug supply shortages.
To learn more about the topics in this episode:
<ul>
<li><a href="https://www.fiercepharma.com/manufacturing/bora-plants-its-flag-us-210m-acquisition-generics-manufacturer-upsher-smith" data-cke-saved-href="https://www.fiercepharma.com/manufacturing/bora-plants-its-flag-us-210m-acquisition-generics-manufacturer-upsher-smith">Bora plants its flag in the US with $210M acquisition of generics manufacturer Upsher-Smith</a></li>
<li><a href="https://www.fiercepharma.com/manufacturing/emergent-pivoting-away-cdmo-sells-baltimore-site-acquisitive-bora-30m" data-cke-saved-href="https://www.fiercepharma.com/manufacturing/emergent-pivoting-away-cdmo-sells-baltimore-site-acquisitive-bora-30m">Emergent, pivoting away from CDMO business, sells Baltimore plant to acquisitive Bora for $30M</a></li>
</ul>

A closer look at 'friend-shoring' and the drug shortage challenge

Each June, the American Society of Clinical Oncology (ASCO) hosts a conference that gathers physicians, researchers and the cancer community to share their latest research on treatments, technologies and more. 

The Fierce team is always on the ground at the ASCO meeting, and this year, Fierce Biotech’s Gabrielle Masson and Fierce Pharma’s Angus Liu covered the event. 

In this week's episode of "The Top Line," they discuss the most talked-about data drops at ASCO and share on-the-ground details, including their experience with Gilead’s virtual reality Trodelvy ride. 

To learn more about the topics in this episode: 
Akeso, Summit's Keytruda win draws 'explosive' interest at ASCO. But what does Merck think?
ASCO: After Keytruda, Merck builds 3-pronged cancer strategy starring Moderna-partnered vaccine
ASCO: Cautious Big Pharmas double down on past wins—steering clear of radioligands and cell therapy

Each June, the American Society of Clinical Oncology (ASCO) hosts a conference that gathers physicians, researchers and the cancer community to share their latest research on treatments, technologies and more. 
The Fierce team is always on the ground at the ASCO meeting, and this year, Fierce Biotech’s Gabrielle Masson and Fierce Pharma’s Angus Liu covered the event. 
In this week's episode of "The Top Line," they discuss the most talked-about data drops at ASCO and share on-the-ground details, including their experience with Gilead’s virtual reality Trodelvy ride. 
To learn more about the topics in this episode: 
<ul>
<li><a href="https://www.fiercepharma.com/pharma/merck-cmo-akeso-summits-keytruda-head-head-win-maybe-another-option-issue" data-cke-saved-href="https://www.fiercepharma.com/pharma/merck-cmo-akeso-summits-keytruda-head-head-win-maybe-another-option-issue">Akeso, Summit's Keytruda win draws 'explosive' interest at ASCO. But what does Merck think?</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/asco-after-keytruda-merck-builds-3-prong-cancer-strategy-stars-moderna-partnered-vaccine" data-cke-saved-href="https://www.fiercebiotech.com/biotech/asco-after-keytruda-merck-builds-3-prong-cancer-strategy-stars-moderna-partnered-vaccine">ASCO: After Keytruda, Merck builds 3-pronged cancer strategy starring Moderna-partnered vaccine</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/asco-big-pharmas-double-down-past-wins-future-success-and-steer-clear-radioligands-and-cell" data-cke-saved-href="https://www.fiercebiotech.com/biotech/asco-big-pharmas-double-down-past-wins-future-success-and-steer-clear-radioligands-and-cell">ASCO: Cautious Big Pharmas double down on past wins—steering clear of radioligands and cell therapy</a></li>
</ul>

Inside this year’s ASCO: Biggest data drops, trends and the best exhibit booth

The Fierce Pharma Marketing team publishes a special report each year on the top pharmaceutical drug ad spenders. This year’s report, which includes numbers for 2023, was published on Monday.  

AbbVie was the standout in this edition, having spent heavily on ads for Skyrizi and Rinvoq. Overall spending on the top 10 ads also experienced a sizable increase compared to the previous year. 

In this week’s episode of “The Top Line,” Fierce Pharma Marketing Senior Editor Ben Adams and Deputy Editor Andrea Park discuss the report, providing key insights and takeaways.  

To learn more about the topics in this episode:  

The top 10 pharma drug ad spenders for 2023

The Fierce Pharma Marketing team publishes a special report each year on the top pharmaceutical drug ad spenders. This year’s report, which includes numbers for 2023, was published on Monday.  
AbbVie was the standout in this edition, having spent heavily on ads for Skyrizi and Rinvoq. Overall spending on the top 10 ads also experienced a sizable increase compared to the previous year. 
In this week’s episode of “The Top Line,” Fierce Pharma Marketing Senior Editor Ben Adams and Deputy Editor Andrea Park discuss the report, providing key insights and takeaways.  
To learn more about the topics in this episode:  
<a href="https://www.fiercepharma.com/marketing/top-10-pharma-drug-ad-spenders-2023">The top 10 pharma drug ad spenders for 2023</a>

The best biopharma M&A deals

In 1 playlist(s)

The Top Line

Social links

Follow podcast

Recent clips